Mirum Pharmaceuticals
-
Former Shire asset becomes Mirum’s first FDA-approved rare disease drug
Mirum Pharmaceuticals drug Livmarli is now approved to treat pruritus caused by Alagille syndrome, a rare liver disease that can worsen to the point of requiring a transplant. Mirum licensed the drug from Shire in 2018.